Long term Weight Management in Obese Diabetic Patients Osama Hamdy, MD, PhD, FACE
|
|
|
- Lawrence Carr
- 10 years ago
- Views:
Transcription
1 Long term Weight Management in Obese Diabetic Patients Osama Hamdy, MD, PhD, FACE Medical Director, Obesity Clinical Program, Director of Inpatient Diabetes Management, Joslin Diabetes Center Assistant Professor of Medicine Harvard Medical School Boston, Massachusetts, USA
2 2
3 Obesity and Diabetes: the Twin Epidemics Rates of diabetes and obesity are dramatically high worldwide, with an average of 17% of people suffering from obesity 7% of people with diabetes Obesity prevalence rates (2009) Diabetes prevalence rates (2010) % % OECD (2011), Overweight and obesity among adults, in Health at a Glance 2011: OECD Indicators, OECD Publishing. OECD (2011), Diabetes prevalence and incidence, in Health at a Glance 2011: OECD Indicators, OECD Publishing. 3
4 90.0 Number of US Individuals with Obesity 80.0 Number in Millions Women Men Age >20 ys Age CDC/NCHS, National Health and Nutrition Examination Survey,
5 Objectives 1 Can long term weight loss be achieved? 2 What are the keys for long term maintenance of weight loss? 3 Is non surgical weight reduction cost effective? 5
6 Type of Intervention Short term Weight Loss (< 1 year) Advice to change lifestyle.. +/ 5 lbs (2%) Lifestyle intervention program 5 10 lbs (2 5%) Intensive lifestyle intervention program lbs (5 7%) Optimal intensive lifestyle intervention program lbs (10 15%) Long term Weight Loss (4 8 years) Intensive lifestyle intervention program 4.7% Optimal intensive lifestyle intervention program 6.3% 6
7 Weight Losses in ILI were Significantly Greater Than in DSE and Sustained Over a 4 year Period (Look AHEAD Study) Time (years) Weight change from baseline (%) *P <0.001 * * * * 7 Look Ahead Research Group. Arch Intern Med. 2010;170(17):
8 Weight Loss Through Year 8 (Look AHEAD study) Percent Reduction in Initial Weight DSE P<.001 for comparisons at all years ILI -2.1% -4.7% Years 8 Adapted with permission from Wadden TA, et al. Obesity. 2011;19:1987.
9 Four Year Weight Loss Trajectories of 887 ILI Participants Who Had Lost 10% Initial Weight at Year 1 Percentage Weight Loss Gained 0-5% 5-6.9% 7-10% 10% Wadden TA et al. Obesity 2011;19: Years N=88 (9.9%) N=174 (19.6%) N=99 (11.2%) N=152 (17.1%) N=374 (42.2%) 9
10 0 Long term Reduction in Body Weight after Optimal Lifestyle Intervention in Clinical Practice -5 Weight Loss in Pounds (-6.3%) W 3 M 6 M 9 M 12 M 15 M 18 M 21 M 24 M 27 M 30 M 33 M 36 M 39 M 42 M 45 M 48 M Total N= Hamdy O. et al. ADA, Philadelphia, 2012
11 0-5 Long term Reduction in Body Weight after Optimal Lifestyle Intervention in Clinical Practice Weight Regain (52% of Participants) -8.0 (-3.3%) Weight Loss in Pounds * * ** ** *** ********* 0 12 W 3 M 6 M 9 M 12 M 15 M 18 M 21 M 24 M 27 M 30 M 33 M 36 M 39 M 42 M 45 M 48 M Group A Group B Total ** Total Group (-6.3%) Weight Maintenance (48% of Participants) * ** * ** ** ** (-9.5%) N= 120 (Group A 57, Group B 63) A versus B * p<0.05, ** P<0.01, *** P<0.001 Hamdy O. et al. ADA, Philadelphia,
12 Distribution of Levels of Weight Maintenance at 1 Year and 2 Year Follow up Assessments by Method of Initial Weight Loss Lost >5.0 Kg Maintain +4.9 Kg Gain >5 Kg Lost >5.0 Kg Maintain +4.9 Kg Gain >5 Kg Year 1 Year 2 NWCR registry: Weight loss >13.6 and maintaining 13.6 kg for a year Average weight loss 56 kg and maintenance of >13.6 kg for 5.5 years Bond DS et al. Int J Obes Jan;33(1):
13 Keys to Optimal Lifestyle Intervention for Long term Weight Reduction 1. Aim for meaningful weight loss goal (5 10%) 2. Gradual and balanced and individualized physical activity 1. Duration of exercise 2. Type of exercise 3. Exercise records 3. Structured dietary intervention & modified macronutrient composition 1. Relatively higher protein, LGI & higher fibers 2. Provided menus 3. Food records 4. Diabetes specific meal replacement (GTSN) 4. Medication adjustment and frequent BG monitoring 5. Counseling and cognitive behavioral change 6. Group intervention and frequent participant contact 7. Daily weighing 13
14 1 Aim for Modest Weight Loss through Defining a SMART Goal Effect of weight loss on insulin sensitivity * Change From Baseline (%) * * * Weight BMI W/H Insulin Sensitivity BMI = body mass index; W/H = waist-to-hip-ratio. *P<0.001 Hamdy O, et al. Diabetes Care. 2003;26:
15 2 Gradual, balanced and individualized physical activity Duration of exercise Type of exercise Short versus long bouts of exercise Exercise records/exercise monitor Visceral Fat The benefits of Exercise and or Increased Physical Activity include BP & lipids Metabolic Control Physical Fitness & QOL Maintenance of Weight Loss Vascular Resistance 15
16 Diabetes, a Common Comorbidity, Significantly Accelerates Loss of Muscle Mass, Strength and Quality Loss of Muscle Mass (gm/year) * * Loss of Total Muscle Mass [g/ year] p<0.05* Park SW, et al. Diabetes Care 2009;32:
17 Exercise Preserves Muscle Mass During Weight Reduction *P<0.05 Loss of Muscle Mass (As % of Total Weight Loss) Men Women Diet Diet + Exercise 17 Ballor DL and Poehlman ET. Int J Obes Relat Metab Disord. 1994;18(1):35-40.
18 Balanced Exercise Model Flexibility Aerobic Strength Stretching Yoga Walking Swimming Biking Dancing Resistance tubing Weight lifting Yoga Strength exercise is particularly important during weight reduction 18
19 Gradual and balanced exercise intervention* Independent Exercise Progression Week Frequency of Exercise* Duration of Exercise Type of Exercise days /wk min AEX + STCH + CST + CT days /wk min AEX + CT+ IT + STCH + Y + CSE days /wk min IT + CT + CSE +SS + Y + STCH AEX Aerobic Exercise SS Superset Training IT Interval Training CSE Core Stability Exercise CT Circuit Training STCH Stretching Exercise CST Cross Training Y Yoga (Vinyasa flow) * Model used in the Why WAIT program 19 Shahar J et al, ADA 2009
20 Changes in % Body Fat, Fat Mass & Lean/Fat Ratio after 12 Weeks of Balanced Exercise Plan Fat Mass (lbs) Body Fat (%) Lean/Fat Ratio * Body Fat Mass in lbs *** *** n = 85 * p <0.05 ** p <0.01 *** p <0.001 Hamdy O et al Obesity Management J. 2008; 4(4):
21 Percent Weight Loss for Categories of 24 month Physical Activity (N = 170) 21 Jakicic JM et alarch Intern Med. 2008; 168(14):
22 Effect of Long vs. Short Bouts of Exercise on Adherence and Weight Loss 10 Activity (min/week) Weight Loss (kg) Long Bouts Short Bouts Long Bouts Short Bouts 0 Long bout = one 40-min session. Short bout = four 10-min sessions. 22 Jakicic et al. J Obes Relat Metab Disord 1995;19:893.
23 3 Structured dietary intervention & modified macronutrient composition Relatively higher protein, LGI & higher fibers Provide structure menus Calorie replacements Food records Calorie intake Carbs to 40-45% Natural food (dinner menus and snacks) and Calorie Replacement Glycemic index Protein intake to 30% Fiber MUFA Saturated fat and sodium 23
24 Diets with High or Low Protein Content and Glycemic Index for Weight Loss Maintenance (26 weeks) n= 773 Initial weight loss >8% Larsen TM et al. N Engl J Med 2010;363: % protein (LGI/HGI) versus 25% protein (LGI/HGI) 24
25 The Metabolic Effect of Different Protein/Carbohydrates Ratios in Type 2 DM Protein to carbohydrate to fat: 30:40:30 Versus 15:55:30-0.3% -0.8% Total glycated hemoglobin response of subjects to the control (15% protein) and high-protein (30% protein) diets over the 5-wk study period. *Significantly different from the control diet, P < 0.05 The rate of decline was also significantly greater after the high-protein diet, P < Adapted from Gannon MC et al. Amer J Clin Nutr 2003;78:
26 Strong Correlation Between Calorie Replacement and Weight Loss (Look AHEAD Study) Number in the bar is mean number of MRs used in that quartile Reduction in Initial Weight in ill participants (%) MRs MRs = meal replacements. Reproduced with permission from Wadden TA et al. Obesitiy 2009; 17:
27 4 Adjusting medications that affect the body weight Diabetes medications Antidepressants Weight loss medications Avoid weight promoting medications 27
28 Diabetes Medications and Body Weight List A List B 1 Identify Weight Gain Weight Neutral Weight Loss Significant Modest 2 Plan Pioglitazone SUs Glyburide Glipizide Insulin NPH Glargine Regular Aspart Lispro Glulisine SUs Glimepiride Glipizide XL Glinides Repaglinide Nateglinide Insulin Detemir Glulisine (PP) Metformin DPP 4 Inhibitors Sitagliptin Saxaglipitin Linagliptin glucosidase Inhibitors Acarbose Miglitol Colesevelam GLP 1 Analoges Exenatide Exenatide ER Liraglutide Pramlintide Bromocriptine 3 Change Stop, Reduce or Switch Continue Add
29 Results of Optimal Intensive Lifestyle Intervention (OILI) Changes in Metabolic & CV Outcomes 7.5 HbA1c (%) * 6.6 n = 115 * P<0.001 Before After Hamdy O, et al. Curr Diab Rep. 2008;8(5):
30 Cost effectiveness of non surgical and surgical weight management Health Care Cost and Diabetes Related Cost Cost utilization (Hospitalization, Clinic visits) 30
31 Cost effectiveness of Intensive Lifestyle Intervention A 10 year analysis of the Diabetes Prevention Program trial showed lifestyle intervention was cost effective compared with placebo in prevention of diabetes in high risk adults From a payer perspective, investment in lifestyle management for diabetes prevention provides good value 31 The Diabetes Prevention Program Research Group. Diabetes Care. 2012;35:
32 Economic Impact of Non Surgical Weight Loss in One Year in Patients With Diabetes Cost Saving (1% wt loss) Estimated Saving with (7% wt loss) Cost saving per year (-3.6%) 1* (-5.8%) 2* (-44%) (-27%) Health Care Cost Diabetes Related Cost 1) p<0.5 2) p<001 YU AP et al. Curr Med Res Opin. 2007;23(9):
33 Impact of Bariatric Surgery on Healthcare Utilization & Costs in Patients with DM over 6 Years 7,806 patients with diabetes who received bariatric surgery Odds of Hospitalization Ratio of Counts of PCP Visits Ratio of Counts of Specialist Conclusion In the six years following bariatric surgery, individuals with type 2 diabetes did not have lower healthcare costs than before surgery. 33 Bleich SN et al. Med Care. 2012, 50(1):58-65
34 In Conclusion Long-term weight reduction can be achieved through nonsurgical weight management Exercise type and duration significantly impact long-term weight maintenance Changing macronutrient compositions, providing structured meal plan plus adding calorie replacements are effective dietary intervention Adjusting diabetes medications is important for effective long-term weight reduction in patients with diabetes Long-term weight reduction is costeffective for prevention and treatment of diabetes 34
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE
DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE 40 yo woman, BMI 36. Motivated to begin diet therapy. Which of the following is contraindicated: Robert B. Baron MD MS Professor and
Diabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
Update on the management of Type 2 Diabetes
Update on the management of Type 2 Diabetes Mona Nasrallah M.D Assistant Professor, Endocrinology American University of Beirut 10 th Annual Family Medicine Conference October 14,2011 Global Prevalence
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
How To Treat Diabetes
Overview of Diabetes Medications Marie Frazzitta DNP, FNP c, CDE, MBA Senior Director of Disease Management North Shore LIJ Health Systems Normal Glucose Metabolism Insulin is produced by beta cells in
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012
Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 In 2002, SETMA began a relationship with Joslin Diabetes
Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes
Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Objectives Pathophysiology of Diabetes Acute & Chronic Complications Managing acute emergencies Case examples 11/24/2014 UWHealth
Insulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy
Insulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy Eric RENARD, MD, PhD Endocrinology Dept, Lapeyronie Hospital Montpellier, France [email protected] Type 2
A Calorie is a Calorie Or is It? 6 th Biennial Childhood Obesity Conference, June 30, 2011
A Calorie is a Calorie Or is It? 6 th Biennial Childhood Obesity Conference, June 30, 2011 Jeff S. Volek, Ph.D., R.D. Human Performance Laboratory Department of Kinesiology University of Connecticut Storrs,
Recommendations for Prescribing Exercise to Overweight and Obese Patients
10 Recommendations for Prescribing Exercise to Overweight and Obese Patients 10 10 Recommendations for Prescribing Exercise to Overweight and Obese Patients Effects of Exercise The increasing prevalence
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
Reversing type 2 diabetes: pancreas composition and function during return to normal glucose tolerance
Reversing type 2 diabetes: pancreas composition and function during return to normal glucose tolerance Dr Sarah Steven Clinical Research Fellow to Professor Roy Taylor Observations from bariatric surgery
Dietary Composition for Weight Loss and Weight Loss Maintenance
Dietary Composition for Weight Loss and Weight Loss Maintenance Bridget M. Hron, MD Instructor in Pediatrics, Harvard Medical School Staff Physician in Gastroenterology & Nutrition and New Balance Foundation
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
Type 2 Diabetes: the pandemic waiting to happen
7 th DIETS/EFAD Conference Type 2 Diabetes: the pandemic waiting to happen Cathy Breen EFAD ESDN Diabetes Lead/Irish Nutrition and Dietetic Institute/ Endocrine Unit, St Columcille s Hospital, Loughlinstown,
Which drugs should be used to treat diabetes in cirrhotic patients?
Which drugs should be used to treat diabetes in cirrhotic patients? Frankfurt am Main 10-12 September 2015 Jörg Bojunga Medizinische Klinik I Johann Wolfgang Goethe-Universität Frankfurt am Main Significance
The basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075
Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date
FYI: (Acceptable range for blood glucose usually 70-110 mg/dl. know your institutions policy.)
How Insulin Works: Each type of insulin has an onset, a peak, and a duration time. Onset is the length of time before insulin reaches the bloodstream and begins lowering blood Peak is the time during which
Type 2 diabetes Definition
Type 2 diabetes Definition Type 2 diabetes is a lifelong (chronic) disease in which there are high levels of sugar (glucose) in the blood. Type 2 diabetes is the most common form of diabetes. Causes Diabetes
Diabetes and Obesity. The diabesity epidemic
Diabetes and Obesity Frank B. Diamond, Jr. M.D. Professor of Pediatrics University of South Florida College of Medicine The diabesity epidemic Prevalence of diabetes worldwide was over 135 million people
Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
Diabetes: Medications
Diabetes: Medications Presented by: APS Healthcare Southwestern PA Health Care Quality Unit (APS HCQU) May 2008 sh Disclaimer Information or education provided by the HCQU is not intended to replace medical
Adult Weight Management Training Summary
Adult Weight Management Training Summary The Commission on Dietetic Registration, the credentialing agency for the Academy of Nutrition and Dietetics Marilyn Holmes, MS, RDN, LDN About This Presentation
Noninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause hypoglycemia MED GROUP DESCRIPTOR
Noninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause MED GROUP DESCRIPTOR INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) MICRONIZED GLYBURIDE*
Add: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above
Guidelines for Type Diabetes - Diagnosis Fasting Plasma Glucose (confirm results if borderline) HbAIC Normal FPG < 00 < 5.5 Impaired Fasting Glucose (IFG) 00 to < 5.7%-.5% Diabetes Mellitus (or random
4/11/14. Medical Director, Bariatric Surgery Mountainview Regional Medical Center. ! None. ! Discuss the ongoing epidemic of obesity
Medical Director, Bariatric Surgery Mountainview Regional Medical Center! None! Discuss the ongoing epidemic of obesity! Discuss current treatment options! Discuss the role of bariatric surgery! Review
Dr. John Bucheit, Pharm.D., BCACP, CDE Clinical Assistant Professor Mercer University College of Pharmacy
Dr. John Bucheit, Pharm.D., BCACP, CDE Clinical Assistant Professor Mercer University College of Pharmacy Disclosures to Participants Requirements for Successful Completion: For successful completion,
BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS
BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS C O N T A C T D I A B E T E S S E R V I C E S F O R M O R E I N F O R M A T I O N 8 4 7-9 1 7-6 9 0 7 THIS SLIDE PRESENTATION WAS PREPARED BY SUE DROGOS,
Diabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
Weight Loss Surgery and Bariatric Nutrition. Jeanine Giordano, MS, RD, CDN
Weight Loss urgery and Bariatric Nutrition Jeanine Giordano, M, RD, CDN UA: Mean BMI trends (age standardized) Prevalence of Obesity Among Adults United tates 68% Australia 59% Russia 54% United Kingdom
Antidiabetic Drugs. Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Antidiabetic Drugs Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Diabetes Mellitus Two types Type 1 Type 2 Type 1 Diabetes Mellitus Lack of insulin production
Diabetes Prevention in Latinos
Diabetes Prevention in Latinos Matthew O Brien, MD, MSc Assistant Professor of Medicine and Public Health Northwestern Feinberg School of Medicine Institute for Public Health and Medicine October 17, 2013
Insulin Initiation and Intensification
Insulin Initiation and Intensification ANDREW S. RHINEHART, MD, FACP, CDE MEDICAL DIRECTOR AND DIABETOLOGIST JOHNSTON MEMORIAL DIABETES CARE CENTER Objectives Understand the pharmacodynamics and pharmacokinetics
10/30/2012. Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University of South Alabama Mobile, Alabama
Faculty Medications for Diabetes Satellite Conference and Live Webcast Wednesday, November 7, 2012 2:00 4:00 p.m. Central Time Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University
Insulin Receptor Substrate 1 (IRS1) Gene Variation Modifies Insulin Resistance Response to Weight-loss Diets in A Two-year Randomized Trial
Nutrition, Physical Activity and Metabolism Conference 2011 Insulin Receptor Substrate 1 (IRS1) Gene Variation Modifies Insulin Resistance Response to Weight-loss Diets in A Two-year Randomized Trial Qibin
SHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
Intensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
Let s Talk About Meters and Meds. Adapted for Upstate Medical University by: Kristi Shaver, BS, RN, CDE, MS-CNS Student (2014) January 2014
Let s Talk About Meters and Meds Adapted for Upstate Medical University by: Kristi Shaver, BS, RN, CDE, MS-CNS Student (2014) January 2014 How to monitor diabetes control: Hemoglobin A 1 C, or just A 1
Insulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB
Insulin switch & Algorithms Rotorua GP CME June 2011 Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Goal of workshop Insulin switching make the necessary move Ensure participants are confident with Recognising
Primary Care Type 2 Diabetes Update
Primary Care Type 2 Diabetes Update May 16, 2014 Presented by: Barb Risnes APRN, BC-ADM, CDE Objectives: Discuss strategies to address common type 2 diabetes patient management challenges Review new pharmacological
Workshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
Intensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
Managing Patients Newly Diagnosed with Diabetes. Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON
Managing Patients Newly Diagnosed with Diabetes Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON 1 Conflict Disclosure Information Conflict Disclosure Information
Intensifying Insulin In Type 2 Diabetes
Intensifying Insulin In Type 2 Diabetes Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine University of North Dakota School of Medicine and Health Sciences Assistant
Fundamentals of Diabetes Care Module 5, Lesson 1
Module 5, Lesson 1 Fundamentals of Diabetes Care Module 5: Taking Medications Healthy Eating Being Active Monitoring Taking Medication Problem Solving Healthy Coping Reducing Risks Foundations For Control
Beating insulin resistance through lifestyle changes
Beating insulin resistance through lifestyle changes This information is relevant to people at risk for type 2 diabetes, those who already have type 2 diabetes, pre- diabetes, polycystic ovary syndrome
Obesity Affects Quality of Life
Obesity Obesity is a serious health epidemic. Obesity is a condition characterized by excessive body fat, genetic and environmental factors. Obesity increases the likelihood of certain diseases and other
The Need for an Integrative Approach to Pediatric Obesity
The Need for an Integrative Approach to Pediatric Obesity David S. Ludwig, MD, PhD Associate Director, Clinical & Translational Studies Unit Director, Optimal Weight for Life (OWL) Program Children s Hospital
TREATMENT STRATEGIES FOR MANAGING TYPE 2 DIABETES MELLITUS. Friday, August 16, 13
TREATMENT STRATEGIES FOR MANAGING TYPE 2 DIABETES MELLITUS 1 Heather Healy, FNP-BC Martha Shelver, CS, ACNP-BC Saint Alphonsus Regional Medical Center 2 OBJECTIVES 3 Review the current management algorithms
Pharmaceutical Management of Diabetes Mellitus
1 Pharmaceutical Management of Diabetes Mellitus Diabetes Mellitus (cont d) Signs and symptoms 2 Elevated fasting blood glucose (higher than 126 mg/dl) or a hemoglobin A1C (A1C) level greater than or equal
Medical Nutrition Therapy for Diabetes
Medical Nutrition Therapy for Diabetes Marion J. Franz, MS, RD, CDE [email protected] Objectives: Discuss expected outcomes and when to evaluate effectiveness of MNT Review macronutrient questions Select
INSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
A Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or
A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl
Diabetes Treatments: Options for Insulin Delivery. Bonnie Pepon, RN, BSN, CDE Certified Diabetes Educator Conemaugh Diabetes Institute
Diabetes Treatments: Options for Insulin Delivery Bonnie Pepon, RN, BSN, CDE Certified Diabetes Educator Conemaugh Diabetes Institute Diabetes 21 million people in the U.S. have diabetes $132 billion each
Insulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE [email protected]
Insulin: Breaking Barriers Enhancing Therapies Jerry Meece, RPh, FACA, CDE [email protected] Questions To Address Who are candidates for insulin? When do we start insulin? How do the different types of
Isagenix Clinical Research Summary Suk Cho, Ph.D., Eric Gumpricht, Ph.D., David Despain, M.Sc.
Isagenix Clinical Research Summary Suk Cho, Ph.D., Eric Gumpricht, Ph.D., David Despain, M.Sc. UIC study finds subjects on Isagenix products lost more body fat, lost more visceral fat, showed greater adherence,
Diabetes Fundamentals
Diabetes Fundamentals Prevalence of Diabetes in the U.S. Undiagnosed 10.7% of all people 20+ 23.1% of all people 60+ (12.2 million) Slide provided by Roche Diagnostics Sources: ADA, WHO statistics Prevalence
The Arguments: T2DM - tremendous economic burden globally Lifestyle / Pharm Rx:
James Cromie The Arguments: T2DM - tremendous economic burden globally Lifestyle / Pharm Rx: INEFFECTIVE and UNSUSTAINED Bariatric surgery is an Effective and Durable treatment option Well established
Effective Treatment of Type 2 Diabetes
Faculty Disclosures Effective Treatment of Type 2 Diabetes Mellitus Dr. Milligan disclosed no relevant financial relationships with any commercial interests. Steven Milligan, MD Diplomat, American Board
Harmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
INTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL
INTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL Presented by: Leyda Callejas PGY5 Endocrinology, Diabetes and Metabolism Acknowledgements: Dr. P Orlander Dr. V Lavis Dr. N Shah
abcdefghijklmnopqrstu
The Quality Unit Planning and Quality Division E: [email protected] [email protected] T: 0131-244 2287 abcdefghijklmnopqrstu NHSScotland Board Chief Executives NHSScotland Board Medical
Treatment Approaches to Diabetes
Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point
Understanding Diseases and Treatments with Canadian Real-world Evidence
Understanding Diseases and Treatments with Canadian Real-world Evidence Real-World Evidence for Successful Market Access WHITEPAPER REAL-WORLD EVIDENCE Generating real-world evidence requires the right
Traditional View of Diabetes. Are children with type 1 diabetes obese: What can we do? 8/9/2012. Change in Traditional View of Diabetes
Are children with type 1 diabetes obese: What can we do? Traditional View of Diabetes Type 1 Diabetes ( T1DM) Onset Juvenile Lean Type 2 Diabetes ( T2DM) Onset Adult Obese QI Project Indrajit Majumdar
Weight Loss Surgery DA participants- 18 months later. By: Caitlyn Patrick and Evan Morgan
Weight Loss Surgery DA participants- 18 months later By: Caitlyn Patrick and Evan Morgan Outline Background Obesity Comorbidities Treatments Barriers to care Kylee Miller s work PDSA Plan: Systematic follow
Diabetes, Type 2. RelayClinical Patient Education Sample Topic Diabetes, Type 2. What is type 2 diabetes? How does it occur?
What is type 2 diabetes? Type 2 diabetes is a disorder that happens when your body does not make enough insulin or is unable to use its own insulin properly. The inability to use insulin is called insulin
The South Asian Indian Women s s Weight Loss Study. Latha Palaniappan, MD, MS BIRCWH Scholar October 20, 2005
The South Asian Indian Women s s Weight Loss Study Latha Palaniappan, MD, MS BIRCWH Scholar October 20, 2005 South Asian Emigrants and second generation from India Bhutan Bangladesh Maldives Nepal Pakistan
Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.
International Diabetes Federation Diabetes Background Information Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.
Is Insulin Effecting Your Weight Loss and Your Health?
Is Insulin Effecting Your Weight Loss and Your Health? Teressa Alexander, M.D., FACOG Women s Healthcare Associates www.rushcopley.com/whca 630-978-6886 Obesity is Epidemic in the US 2/3rds of U.S. adults
Bariatric Surgery. OHTAC Recommendation. Bariatric Surgery
OHTAC Recommendation Bariatric Surgery January 21, 2005 1 The Ontario Health Technology Advisory Committee (OHTAC) met on January 21, 2005 and reviewed bariatric surgery for morbid obesity. Obesity is
Diabetes may be classified as. i) Type - I Diabetes mellitus. Type - II Diabetes mellitus. Type - 1.5 Diabetes mellitus. Gestational Diabetes INSULIN
HYPOGLYCEMIC AGENT Diabetes mellitus is a chronic metabolic disorder of multiple aetiology characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting
Guidelines for Type 2 Diabetes Diagnosis
Guidelines for Type 2 Diabetes Diagnosis Fasting Plasma Glucose (in asymptomatic individuals, repeat measurement to confirm the test) Normal FPG < 100 2-hr OGTT < 140 HbA1C < 5.5% Impaired Fasting Glucose
Carbohydrate Counting. Who chooses what you eat every day? Setting The Stage. Pre-Test. Pre-Test. Eating for Diabetes Made Easier
Carbohydrate Counting Eating for Diabetes Made Easier Kris Williams, MS RD Department of Health Education Kaiser Permanente, Kern County Setting The Stage Who chooses what you eat every day? Pre-Test.
Should We Count Fat and Protein in Bolus Insulin Dose Calculation: Does Carbohydrate Counting Work? Howard A. Wolpert, MD
Should We Count Fat and Protein in Bolus Insulin Dose Calculation: Does Carbohydrate Counting Work? Howard A. Wolpert, MD Carbohydrate to Insulin Ratio, circa 1935 Standard Insulin Replacement Regimen
Approximate Cost Reference List i for Antihyperglycemic Agents
Alpha Glucosidase Inhibitor Acarbose (Glucobay ) Biguanides Metformin (Glucophage, generic) Metformin ER (Glumetza ) Approximate Cost Reference List i for Antihyperglycemic Agents Incretin Agents - DPP-4
The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery
The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery Michael E. Farkouh, MD, MSc Peter Munk Chair in Multinational Clinical Trials Director, Heart and Stroke
Comparative Review of Oral Hypoglycemic Agents in Adults
SECTION 18.5 Comparative Review of Oral Hypoglycemic Agents in Adults Harinder Chahal For WHO Secretariat Table of Contents Acronyms:... 3 I. Background and Rationale for the review:... 4 II. Medications
Information for Patients
Information for Patients Guidance for Diabetic Persons having bowel preparation for a flexible sigmoidoscopy or a colonoscopy or a combined gastroscopy and colonoscopy This guidance is provided to assist
Dieting and Gallstones
Dieting and Gallstones WIN Weight-control Information Network What are Gallstones are clusters of solid material that form in the gallbladder. The most common type is made mostly of cholesterol. Gallstones
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
